Trials / Withdrawn
WithdrawnNCT02584777
A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis
A Phase II, Prospective, Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Asian Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post- Essential Thrombocythemia Myelofibrosis
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Baxalta now part of Shire · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of pacritinib in Asian subjects with myelofibrosis (MF), which includes primary MF (PMF), post-polycythemia vera MF (PPV-MF) or post-essential thrombocythemia MF (PET-MF).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Pacritinib | QD (Once a day) |
Timeline
- Start date
- 2015-11-30
- Primary completion
- 2017-09-30
- Completion
- 2020-08-31
- First posted
- 2015-10-23
- Last updated
- 2021-05-05
Source: ClinicalTrials.gov record NCT02584777. Inclusion in this directory is not an endorsement.